"Its drug discovery portfolio which has expanded into several new therapeutic areas such as major depressive disorder (MDD), obesity and pain through neuronal nicotinic receptor modulators resulted in the grant of one product patent from USA and one patent from South Korea," said the company in its filing.
In the last week the company was also selected as Best Under A Billion" companies by Forbes Asia 2014".
The stocks opened at Rs 183 and hit a high of Rs 192.50 while around 15,00,000 shares have changed hands on BSE and NSE combined, so far.